Prelude Therapeutics Collaborates With Merck To Evaluate PRT3789 Combined With KEYTRUDA (Pembrolizumab) In Patients With SMARCA4-Mutated Cancers
Prelude Therapeutics Collaborates With Merck To Evaluate PRT3789 Combined With KEYTRUDA (Pembrolizumab) In Patients With SMARCA4-Mutated Cancers
Prelude Therapeutics與默沙東合作評估PRT3789聯合KEYTRUDA（Pembrolizumab）治療SMARCA4突變癌症患者。
Combining a first-in-class, highly selective SMARCA2 degrader with an anti-PD-1 therapy may potentially enhance the anti-tumor activity of either agent because of the complementary nature of the two mechanisms.
將首個高度選擇性SMARCA2降解劑與抗PD-1療法相結合，可能會增強兩種機制的互補作用，從而提高抗腫瘤活性。
Prelude will sponsor the clinical trial and Merck will provide KEYTRUDA.
Prelude將贊助臨床試驗，默沙東則提供KEYTRUDA。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。